Cellectis S.A. American Depositary Shares (CLLS)
Company News
Cellectis présente une stratégie innovante d'ingénierie des cellules T qui exploite les propriétés pro-inflammatoires de l'interleukine 2 (IL-2) dans l'objectif d'améliorer l'efficacité des cellules CAR T contre les tumeurs solides.
Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&P 500 also rose, gaining, 0.67% to 4,221.94. Check This Out: $2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying  Leading and Lagging Sectors Information technology shares jumped by 1.2% on Wednesday. In trading on Wednesday, materials shares fell by 0.6%.  Top Headline The Federal Reserve opted to maintain interest rates at the range of 5.25% to 5.5% during its November meeting, as widely anticipated by the market.  Equities Trading UP Cellectis S.A. (NASDAQ: CLLS) shares shot up 194% to $2.8335. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting. Shares of Patriot Transportation Holding, Inc. (NASDAQ: PATI) got a boost, shooting 103% to $15.59. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash. TG Therapeutics, Inc. (NASDAQ: TGTX) shares were also up, gaining 32% to $10.18 following ...
Penny stocks to watch this week. The post 5 Most Active Penny Stocks Today & Why They’re Moving Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.